ESMO 2023
Research and breaking news from the European Society for Medical Oncology Congress, taking place in Madrid, Spain, October 20-24, 2023.
Participating patients received PERT at baseline or within 3 months of receiving first-line treatment.
Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.
Advertisement
Advertisement